Clinical Trials Logo

Catheter-Related Infections clinical trials

View clinical trials related to Catheter-Related Infections.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02899780 Withdrawn - Clinical trials for Catheter-Related Infections

Treatment of Infected Dialysis Catheters With Fiber Optic Ultraviolet Light

Start date: May 11, 2017
Phase: N/A
Study type: Interventional

This study is a first-in-man clinical trial using fiber optically delivered ultraviolet light for reducing viable bacteria within indwelling tunneled dialysis catheters.

NCT ID: NCT02697162 Withdrawn - Neurogenic Bladder Clinical Trials

Antiseptic-coated Intermittent Urinary Catheter

GuardianCath
Start date: June 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Study design is a prospective, randomised, double-blind, and interventional. Primary aim of the study is to investigate efficacy of antiseptic-coated intermittent hydrophilic urinary catheters in prevention and reduction of catheter-associated urinary tract infections in children with neurogenic bladder. Secondary aim is to assess feasibility of antiseptic-coated intermittent hydrophilic urinary catheters in neurogenic bladder management. Octenidine chloride will be used as antiseptic.

NCT ID: NCT01772875 Withdrawn - Clinical trials for Catheter Related Infections

Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients

Start date: January 2013
Phase: N/A
Study type: Interventional

In patients with advanced multiple sclerosis, permanent urinary catheters are often used to manage the urinary incontinence and bladder emptying problems. These catheters will lead to urinary tract infection, blocking of the catheter etc.. Especially infections with certain bacteria such as proteus, enterobacteriaceae and ESBL producing enterobacteriaceae and pseudomonas can pose a problem for the hospital infection control and for the patient. This study wants to evaluate the potential role of regular bladder lavage with saline, a solution of betadine, an acid solution of acetic acid and of URotainer Twin Suby G ( Braun)in the decontamination of these bladders and the prevention of clinically relevant urinary tract infections.

NCT ID: NCT01263574 Withdrawn - Clinical trials for Short Bowel Syndrome

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This study is designed to determine if the use of 70% ethanol lock solution in central lines decreases the rate of central line infections in children with short bowel syndrome. While ethanol locks have been used safely in children, there has been no published research to date that clearly shows it is of definite benefit in this group of patients.

NCT ID: NCT00878683 Withdrawn - Intensive Care Clinical Trials

Novel Device for Reducing Catheter-Related Infections

Start date: July 2009
Phase: N/A
Study type: Interventional

This study is a pilot study of the safety, tolerability and efficacy of an investigational central venous catheter device used in conjunction with a standard central venous catheter. The hypothesis is that utilization of a catheter device incorporating cyanoacrylate will reduce catheter colonization by bacteria, and may decrease the rate of catheter-related bloodstream infections.

NCT ID: NCT00378781 Withdrawn - Cancer Clinical Trials

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Start date: n/a
Phase: N/A
Study type: Interventional

RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection. It is not yet known whether heparin is more effective than M-EDTA in preventing catheter-related infections and blockages in patients at high risk for a catheter-related infection. PURPOSE: This randomized clinical trial is studying heparin to see how well it works compared with M-EDTA in preventing catheter-related infections and blockages in patients at high risk for a catheter-related infection.